Chronic myeloid leukemia and imatinib: Experience at the lome campus teaching hospital (Togo);Leucémie myéloïde chronique et imatinib, expérience du CHU campus de lome ́ au Togo

Medecine et Sante Tropicales

Volumn 22, Issue 3, 2012, Pages 307-311

  Segbena, A Y ^a,b   Kueviakoe, I M D ^a,b   Agbetiafa, K ^b   Padaro, E ^b   Layibo, Y ^b   Dorkenoo, A ^b   Agbo, Y M ^b   Bories, D ^c  

^a L'université de Lomé   (Togo)

^b Unité d'hématologie   (Togo)

^c HENRI MONDOR HOSPITAL   (France)

Author keywords

Chronic myeloid leukemia (CML); Imatinib; Lom ; Togo

Indexed keywords

ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; IMATINIB; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHRONIC MYELOID LEUKEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PROSPECTIVE STUDY; TOGO;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; BENZAMIDES; CHILD; FEMALE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PIPERAZINES; PROSPECTIVE STUDIES; PYRIMIDINES; TOGO; YOUNG ADULT;

EID: 84871628983     PISSN: 22613684     EISSN: 22612211     Source Type: Journal    
DOI: 10.1684/mst.2012.0083     Document Type: Article

References (27)

1. Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
2. Anon H. Gleevec (STI-571) pour le traitement des leucémies myéloïdes chroniques. La lettre médicale 2001; 25: 23-26.
3. Labussiere H, Hayette S, Tigaud I, Michallet M, Nicolini FE. Le traitement de la leucémie myéloïde chronique en 2007. Bull Cancer 2007; 94: 863-869.
4. Curran M, Croom K, Goa K. Imatinib Mesylate: A Review of Its Use in Chronic Myeloid Leukemia. Am J cancer 2003; 2: 439-454.
5. Kueviakoe IM, Baite K, Agbetiafa K, Vovor A, Segbena AY. Panorama des hémopathies malignes diagnostiquées au myélogramme dans les CHU de Lomé sur une période de 12 ans. Revue Togolaise des Sciences 2006; 1: 57-68.
6. Cortes J, Talpaz M, O'Brien S, et al. Molecular responses in patients with chronic myelogenous leukemia in chronic phase treated with imatinib mesylate. Clin Cancer Res 2005; 11: 3425-3432.
7. Goldman JM. How I treat chronic myeloid leukemia in the imatinib era. Blood 2007; 110: 2828-2837.
8. Simonsson B, Kloke O, Stahel RA. ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of chronic myelogenous leukemia (CML). Ann Oncol 2005; 16 Suppl 1: i52-i53.
9. Mukiibi JM, Nyirenda CM, Paul B, Adewuyi JO, Mzula EL, Malata HN. Chronic myeloid leukaemia in central Africans. East Afr Med J 2003; 80: 470-475.
10. Diagne I, Diagne-Gueye NR, Gaye-Ly K, et al. Problèmes posés par la prise en charge des hémopathies malignes chez l'enfant au Sénégal. Dakar Med 2002; 47: 12-17.
11. Diop S, Ndoura A, Toure Fall AO, Thiam D, Diakhate L. Bone Marrow aspiration in diagnosis of hemopathies in Dakar, Senegal. Dakar Med 2004; 49: 106-169.
12. Usman M, Kakepoto GN, Adil SN, Sajid R, Arain S, Khurshid M. Hematologic and cytogenetic findings in eleven chronic myelogenous leukemia patients treated with imatinib mesylate at a tertiary care hospital. J Pak Med Assoc 2004; 54: 17-20.
13. Tardieu S, Brun-Strang C, Berthaud P, et al. Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiol Drug Saf 2005; 14: 545-553.
14. Sureda A, Carrasco M, de Miguel M, et al. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia. Haematologica 2003; 88: 1213-1220.
15. Chang YH, Lu MY, Jou ST, Lin DT, Lin KH, Tien HF. Forty-seven children suffering from chronic myeloid leukemia at a center over a 25-year period. Pediatr Hematol Oncol 2003; 20: 505-515.
16. Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med 1999; 131: 207-219.
17. Tothova E, Kafkova A, Fricova M, Benova B, Kirschnerova G, Tothova A. Imatinib mesylate in Philadelphia chromosome-positive, chronic-phase myeloid leukemia after failure of interferon alpha. Neoplasma 2005; 52: 63-67.
18. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408-2417.
19. Cervantes F, Hernandez-Boluda JC, Steegmann JL, et al. Imatinib mesylate therapy of chronic phase chronic myeloid leukemia resistant or intolerant to interferon: results and prognostic factors for response and progression-free survival in 150 patients. Haematologica 2003; 88: 1117-1122.
20. Morishima Y, Ogura M, Nishimura M, et al. Efficacy and safety of imatinib mesylate for patients in the first chronic phase of chronic myeloid leukemia: results of a Japanese phase II clinical study. Int J Hematol 2004; 80: 261-266.
21. Ault P, Kantarjian H, Welch MA, Giles F, Rios MB, Cortes J. Interleukin 11 May improve thrombocytopenia associated with imatinib mesylate therapy in chronic Myelogenous leukemia. Leuk Res 2004; 28: 613-618.
22. Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukemia: report of two cases. Am J Hematol 2004; 76: 275-278.
23. Terre C, Eclache V, Rousselot P, et al. Report of 34 patients with clonal chromosomal abnormalities in Philadelphia-negative cells during imatinib treatment of Philadelphia-positive chronic myeloid leukemia. Leukemia 2004; 18: 1340-1346.
24. Breccia M, Carmosino I, Russo E, Morano SG, Latagliata R, Alimena G. Early and tardive skin adverse events in chronic myeloid leukaemia patients treated with imatinib. Eur J Haematol 2005; 74: 121-123.
25. Liu D, Seiter K, Mathews T, Madahar CJ, Ahmed T. Sweet's syndrome with CML cell infiltration of the skin in a patient with chronic-phase CML while taking Imatinib Mesylate. Leuk Res 2004; 28 Suppl 1: S61-S63.
26. Kantarjian H, O'Brien S, Cortes J, et al. Analysis of the impact of imatinib mesylate therapy on the prognosis of patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon-alpha regimens for early chronic phase. Cancer 2003; 98: 1430-1437.
27. Higashi T, Tsukada J, Kato C, et al. Imatinib mesylate-sensitive blast crisis immediately after discontinuation of imatinib mesylate therapy in chronic myelogenous leukaemia: report of two cases. Am J Hematol 2004; 76 (3): 275-278.